Market Newsdesk

April 20, 2026 9:08 am

Lumen Technologies, Inc. and Qwest Corporation Announce Commencement of Exchange Offers and Consent Solicitations and Intention to Delist Notes

Lumen Technologies, Inc. and Qwest Corporation Announce Commencement of Exchange Offers and Consent Solicitations and Intention to Delist Notes

DENVER–(BUSINESS WIRE)–Lumen Technologies, Inc. (“Lumen,” “us,” “we” or “our”) (NYSE: LUMN) today announced that it, together with Qwest Corporation (“Qwest”), its wholly-owned subsidiary, has commenced offers to exchange (the “Exchange Offers”) the 6.5% Notes due 2056 (CUSIP Number 74913G 881) (the “2056 Notes”) and 6.75% Notes due 2057 (CUSIP Number 74913G 873) (the “2057 Notes” and, together with the 2056 Notes, the “Old Qwest Notes”) issued by Qwest for 6.500% Notes due 2056 (the “New 2056 Notes”) and 6.750% Notes due 2057 (the “New 2057 Notes” and, together with the New 2056 Notes, the “New Qwest Notes”) to be issued by Qwest, respectively, and to be fully and unconditionally guaranteed on an unsecured basis by Lumen, in each case upon the terms and subject to the conditions set forth in the Prospectus (as defined below). In connection with the Exchange Offers, Qwest and Lumen are also soliciting consents to amend the Old Qwest Indentures (as defined below) (the “Consent Solicitations”). The following table sets forth the consideration to be offered to holders of each series of Old Qwest Notes in the Exchange Offers and the Consent Solicitations:

Aggregate

Principal

Amount

($mm)

Series of Notes

Issued by Qwest to

be Exchanged

(Collectively, the

“Old Qwest Notes”)

CUSIP No.

Series of Notes to be

Issued by Qwest

(Collectively, the

“New Qwest Notes”)

Exchange

Consideration⁽¹⁾

Early

Participation

Premium⁽¹⁾

Early

Consent

Fee⁽²⁾

Early

Exchange

Consideration⁽⁴⁾

New Qwest

Notes⁽³⁾
(principal

amount)

Cash

New Qwest

Notes⁽³⁾
(principal

amount)

Cash

$977,500,000

6.5% Notes due

2056 (the “2056 Notes”)

74913G 881

6.500% Notes due

2056 (the “New 2056 Notes”)

$ 24.25

$ 0.75

$ 0.0625

$ 25

$ 0.0625

$660,000,000

6.75% Notes due

2057 (the “2057 Notes”)

74913G 873

6.750% Notes due

2057 (the “New 2057 Notes”)

$ 24.25

$ 0.75

$ 0.0625

$ 25

$ 0.0625

(1)	Consideration per $25 principal amount of Old Qwest Notes validly tendered, subject to any rounding as described in the Prospectus.
(2)	Consideration in the form of a cash payment of $0.0625 per $25 principal amount of the Old Qwest Notes for consents to the Proposed Amendments (as defined below) to the applicable Old Qwest Indenture under which such series of Old Qwest Notes were issued that are validly delivered prior to the Early Participation Date described below and not validly withdrawn.
(3)	The term “New Qwest Notes” in this column refers, in each case, to the series of New Qwest Notes corresponding to the series of Old Qwest Notes of like tenor and coupon.
(4)	Expressed per $25 principal amount of the Old Qwest Notes. Includes the applicable Early Participation Premium (as defined below) and the applicable Early Consent Fee (as defined below) for each series of Old Qwest Notes validly tendered prior to the Early Participation Date described below and not validly withdrawn.

Each New Qwest Note issued in exchange for an Old Qwest Note will have an interest rate and maturity that are the same as the interest rate and maturity of the tendered Old Qwest Note, as well as the same interest payment dates and redemption prices and will accrue interest from and including the most recent interest payment date of the tendered Old Qwest Note. Each of the Exchange Offers will expire immediately following 5 p.m. ET on May 26, 2026, as it may be extended as described in the Prospectus (the “Expiration Date”).

In exchange for each note (or unit) per $25 principal amount of Old Qwest Notes that is validly tendered prior to 5 p.m. ET on May 8, 2026, as it may be extended as described in the Prospectus (the “Early Participation Date”), and not validly withdrawn, holders will be eligible to receive the early exchange consideration set out in the table above (the “Early Exchange Consideration”), which in each case consists of (i) $25 principal amount of the corresponding New Qwest Notes (including the Early Participation Premiums set out in the table above (collectively, the “Early Participation Premium”), which consists of $0.75 principal amount of the corresponding New Qwest Notes and (ii) a cash payment of $0.0625 (an “Early Consent Fee”).

In exchange for each note (or unit) per $25 principal amount of the Old Qwest Notes that is validly tendered after the Early Participation Date but prior to the Expiration Date and not validly withdrawn, holders will be eligible to receive only the exchange consideration set out in the table above (the “Exchange Consideration”), which is equal to the Early Exchange Consideration less the Early Participation Premium and less the Early Consent Fee, and so consists of $24.25 principal amount of the New Qwest Notes.

Qwest will pay the Early Consent Fee on the Settlement Date (as defined in the Prospectus). Holders of Old Qwest Notes for which no consent is delivered prior to the Early Participation Date (or Old Qwest Notes for which a valid consent is delivered, but such consent is revoked prior to the Early Participation Date) will not receive any Early Consent Fee, even though the Proposed Amendments to the Old Qwest Indentures, if they become operative, will bind all holders of the applicable series of Old Qwest Notes, including any transferees of current holders. Other than the Early Participation Premium and the Early Consent Fee given to holders who validly tender (and do not validly withdraw) their Old Qwest Notes prior to the Early Participation Date, no payment will be made for a holder’s consent to the Proposed Amendments to the Old Qwest Indentures.

Tenders of Old Qwest Notes in connection with any of the Exchange Offers may be withdrawn and consents to the Proposed Amendments may be revoked at any time prior to 5 p.m. ET on May 8, 2026, as it may be extended as described in the Prospectus (the “Withdrawal Deadline”), but may not be withdrawn or revoked at any time thereafter. Consents may be revoked prior to the Withdrawal Deadline only by validly withdrawing the associated tendered Old Qwest Notes. A valid withdrawal of tendered Old Qwest Notes prior to the Withdrawal Deadline will be deemed to be a concurrent revocation of the related consent to the Proposed Amendments to the relevant Old Qwest Indenture, and a revocation of a consent to the Proposed Amendments prior to the Withdrawal Deadline will be deemed to be a concurrent withdrawal of the related tendered Old Qwest Notes. Following the Withdrawal Deadline, tenders of Old Qwest Notes may not be validly withdrawn and consents may not be revoked unless Qwest elects in its sole discretion to amend the Exchange Offers and Consent Solicitations to allow such actions or Qwest is otherwise required by law to permit withdrawal. To the extent Qwest elects to allow additional withdrawal rights after the Withdrawal Deadline, Qwest may elect do so without also allowing additional consent revocation rights.

Qwest will pay a soliciting dealer fee of $0.03 for each note (or unit) per $25 principal amount of the Old Qwest Notes that are validly tendered prior to the Expiration Date and not validly withdrawn to retail brokers that are appropriately designated by their tendering holder clients to receive this fee, provided that such fee will only be paid with respect to tenders by holders whose aggregate principal amount of the Old Qwest Notes is $250,000 or less.

In conjunction with the Exchange Offers, Qwest is soliciting consents from holders of each series of the Old Qwest Notes (“Consents”) to certain proposed amendments (the “Proposed Amendments”) to the indentures governing the Old Qwest Notes (the “Old Qwest Indentures”). Holders of Old Qwest Notes that tender such Old Qwest Notes will be deemed to have given Consent to the Proposed Amendments with respect to the Old Qwest Notes. To adopt the Proposed Amendments related to a series of Old Qwest Notes, Qwest must receive Consents from holders representing at least a majority of the outstanding aggregate principal amount of such series of Old Qwest Notes (the “Requisite Consents”). Receipt of the Requisite Consents is not a condition to the consummation of the Exchange Offers.

If the Requisite Consents are received with respect to any series of Old Qwest Notes, assuming the satisfaction or waiver of the conditions to the Exchange Offer described in the Prospectus, a supplemental indenture, giving effect to the Proposed Amendments with respect to the applicable series of Old Qwest Notes, will be executed and become effective on the Settlement Date. Consents to the Proposed Amendments may be revoked at any time prior to the Withdrawal Deadline, but may not be revoked at any time thereafter. Consents may be revoked only by validly withdrawing the associated tendered Old Qwest Notes prior to the Withdrawal Deadline. A valid withdrawal of tendered Old Qwest Notes prior to the Withdrawal Deadline will be deemed to be a concurrent revocation of the related consent to the Proposed Amendments, and a revocation of a consent to the Proposed Amendments prior to the Withdrawal Deadline will be deemed to be a concurrent withdrawal of the related tendered Old Qwest Notes.

Each New Qwest Note issued in exchange for an Old Qwest Note will have an interest rate and maturity that are the same as the interest rate and maturity of the tendered Old Qwest Note, as well as the same interest payment dates and redemption prices. The New Qwest Notes (i) will be senior unsecured obligations of Qwest, will rank senior to obligations to make payments under any of Qwest’s existing and future subordinated debt, and will rank equally in right of payment with Qwest’s obligations to make payments under all of Qwest’s existing and future unsecured and unsubordinated debt; (ii) will be effectively subordinated in right of payment to any of Qwest’s existing and future secured indebtedness to the extent of the value of the assets securing any such indebtedness; and (iii) will be fully and unconditionally guaranteed on an unsecured basis by Lumen.

Lumen has applied to list the New Qwest Notes on the New York Stock Exchange (“NYSE”). If the application is approved, we expect trading in the New Qwest Notes on the NYSE to begin on the original issue date or promptly thereafter.

As part of Qwest simplifying its reporting obligations, Qwest intends to de-list the Old Qwest Notes from the NYSE, de-register the Old Qwest Notes and cease filing reports with the SEC under the Exchange Act, in reliance on Rule 12h-5 under the Exchange Act, subject to Lumen’s periodic reports containing the disclosures required by Rule 13-01 of Regulation S-X. As such, Lumen has also announced its intention to voluntarily delist from the NYSE the Old Qwest Notes and its intention to file a Notification of Removal from Listing on Form 25 on or about April 30, 2026 (the “Form 25”) with the US Securities and Exchange Commission (the “SEC”). As a result, Lumen expects the delisting of the Old Qwest Notes to become effective on or about May 11, 2026, from which time the Old Qwest Notes will no longer be listed on the NYSE.

The description above includes only a summary of certain key terms of the Exchange Offers, Consent Solicitations and the New Qwest Notes. A Registration Statement on Form S-4, including a prospectus and consent solicitation statement forming a part thereof (the “Prospectus”), which is subject to change, relating to the issuance of the New Qwest Notes has been filed with the SEC (the “Registration Statement”). If and when issued, the New Qwest Notes will be registered under the Securities Act of 1933, as amended.

Copies of the Prospectus pursuant to which the Exchange Offers and Consent Solicitations are being made may be obtained from D.F. King & Co., Inc., the information agent and exchange agent for the Exchange Offers and Consent Solicitations. Requests for documentation and questions regarding procedures for tendering the Old Qwest Notes can be directed to D.F. King & Co., Inc. at (800) 755-3105 (for information U.S. Toll-free) or (212) 257-2075 (information for banks and brokers). Questions regarding the terms and conditions of the Exchange Offers and Consent Solicitations should be directed to the dealer manager, Morgan Stanley & Co. LLC, at Morgan Stanley & Co. LLC, 1585 Broadway, New York, New York 10036, Attention: Global Debt Advisory Group, Collect: (212) 761-1057, Toll Free: (800) 624-1808, Email: [email protected].

The consummation of each Exchange Offer and Consent Solicitation is subject to, and conditioned upon, the satisfaction or, where permitted, waiver of certain conditions, including, among other things, (i) the Registration Statement having been declared effective by the SEC and not being subject to a stop order by the SEC and (ii) the absence of any actual or threatened legal impediment to the acceptance for exchange of, or exchange of, the Old Qwest Notes.

The Exchange Offers and Consent Solicitations are being made only by and pursuant to the terms and subject to the conditions set forth in the Prospectus, which forms a part of the Registration Statement, and the information in this press release is qualified by reference to such Prospectus and the Registration Statement.

This press release is for informational purposes only and is not an offer to buy or sell or the solicitation of an offer to sell with respect to any securities. The solicitation of offers to exchange the Old Qwest Notes for New Qwest Notes is only being made pursuant to the terms of the Exchange Offers. Qwest is not making an offer of New Qwest Notes in any jurisdiction where the Exchange Offers are not permitted, and this press release does not constitute an offer to participate in the Exchange Offers to any person in any jurisdiction where it is unlawful to make such an offer or solicitations.

Holders of the Old Qwest Notes are urged to carefully read the Prospectus before making any decision with respect to the Exchange Offers and Consent Solicitations. None of Lumen, Qwest, the dealer managers, the trustee with respect to any series of Old Qwest Notes, the trustee with respect to any series of New Qwest Notes, the information agent and exchange agent for the Exchange Offers or any affiliate of any of them makes any recommendation as to whether holders of the Old Qwest Notes should exchange their Old Qwest Notes for New Qwest Notes in the Exchange Offers or deliver consents to the Proposed Amendments, and no one has been authorized by any of them to make such a recommendation.

Holders of the Old Qwest Notes must make their own decision as to whether to tender Old Qwest Notes and, if so, the principal amount of Old Qwest Notes to tender.

About Lumen Technologies

Lumen is unleashing the world’s digital potential. We ignite business growth by connecting people, data, and applications – quickly, securely, and effortlessly. As the trusted network for AI, Lumen uses the scale of our network to help companies realize AI’s full potential. From metro connectivity to long-haul data transport to our edge cloud, security, managed service, and digital platform capabilities, we meet our customers’ needs today and as they build for tomorrow. Lumen and Lumen Technologies are registered trademarks of Lumen Technologies, Inc. in the United States.

Forward-Looking Statements

Except for historical and factual information, the matters set forth in this release and other of our oral or written statements identified by words such as “estimates,” “expects,” “anticipates,” “believes,” “plans,” “intends,” and similar expressions are forward-looking statements. These forward-looking statements are not guarantees of future results and are based on current expectations only, are inherently speculative, and are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. Actual events and results may differ materially from those anticipated, estimated, projected or implied by us in those statements if one or more of these risks or uncertainties materialize, or if underlying assumptions prove incorrect. Factors that could affect actual results include, but are not limited to: failure of the conditions set forth in the Registration Statement to be satisfied or waived; the possibility that potential debt investors will not be receptive to the Exchange Offers or Consent Solicitations on the terms described above or at all; corporate developments that could preclude, impair or delay the above-described transactions due to restrictions under the federal securities laws; changes in Qwest or Lumen’s credit ratings; changes in the cash requirements, financial position, financing plans or investment plans of Qwest or Lumen or their respective affiliates; changes in general market, economic, tax, regulatory or industry conditions that impact the ability or willingness of Qwest or Lumen or their respective affiliates to consummate the above-described transactions on the terms described above or at all; and other risks referenced from time to time in the filings of Lumen or Qwest with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise any forward-looking statements for any reason, whether as a result of new information, future events or developments, changed circumstances, or otherwise. We may change our intentions, strategies or plans (including our plans expressed herein) without notice at any time and for any reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260419795716/en/

Media Contact:

Anita J. Gomes

[email protected]

+1 858-229-8538

Investor Contact:

Jim Breen, CFA

[email protected]

+1 603-404-7003

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Software Networks Internet Artificial Intelligence Data Management Technology Other Technology Security

MEDIA:

Logo

April 20, 2026 9:06 am

ADS-TEC Energy at Hannover Messe 2026: Battery-based infrastructure as a response to volatile energy markets

ADS-TEC Energy is exhibiting at the Baden-Württemberg pavilion in Hall 12, Booth E63.

Energy prices remain volatile, increasing pressure on businesses
Battery storage enables flexibility, resilience, and economic independence
ADS-TEC Energy showcases practical solutions for resilient energy infrastructure at Hannover Messe

HANNOVER, Germany & NÜRTINGEN, Germany–(BUSINESS WIRE)–
Energy prices in Europe remain high and difficult to predict. Geopolitical uncertainties and structural dependencies on energy imports are directly impacting companies and their investment decisions. At Hannover Messe 2026 (April 20–24), ADS-TEC Energy demonstrates how battery-based systems can counter this dynamic and why they are becoming a key enabler of scalable energy infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420342686/en/

ADS-TEC Energy is exhibiting at the Baden-Württemberg pavilion in Hall 12, Booth E63.

ADS-TEC Energy is exhibiting at the Baden-Württemberg pavilion in Hall 12, Booth E63. As a German partner, the company takes responsibility for the development, integration, and operation of complex energy systems across their entire lifecycle.

“Made in Germany is not a label of origin for us, but a promise of quality and security,” said Thomas Speidel, CEO of ADS-TEC Energy. “In critical infrastructure, it is about data sovereignty, operational reliability, and the ability to control and develop systems over the long term. This is where we bring in nearly 15 years of experience.”

Energy is increasingly becoming a strategic factor: it is no longer a stable cost block, but a risk that must be actively managed. Companies need to reduce their exposure to external dependencies, Speidel added.

Battery storage systems enable energy to be stored, peak loads to be managed, and electricity to be used when it is economically most beneficial. This increases predictability in volatile markets, reduces dependence on energy imports, and strengthens competitiveness. The combination of storage, charging infrastructure, and energy management also unlocks additional economic value by enabling energy to be actively managed and optimized. Flexibility is becoming a key factor for the economic operation of infrastructure.

A concrete example is showcased at the booth with the ChargePost: the battery-buffered fast charging solution enables charging capacities of up to 300 kW, even with limited grid connections. This makes high-power charging viable where conventional infrastructure reaches its limits, including urban, rural, retail, and fleet environments. With hundreds of charging points deployed, the solution has a proven track record in international markets.

Hannover Messe is one of the world’s leading platforms for industrial transformation. For ADS-TEC Energy, participation sends a clear message: the future of energy systems will not be determined by grid expansion alone, but by flexibility – and by scalable solutions that enable energy to be stored, managed, and monetized.

About ADS-TEC Energy

With more than a decade of experience in lithium-ion technologies, ADS-TEC Energy develops and manufactures battery storage solutions and ultra-fast charging systems, including advanced energy management software. ADS-TEC Energy’s battery-buffered fast-charging technology enables electric vehicles to charge at ultra-high power levels even on weak grids, all within an exceptionally compact design.

Headquartered in Nürtingen, Baden-Württemberg, the company was nominated by the President of Germany for the German Future Prize and was inducted into the “Circle of Excellence” in 2022. The outstanding quality and performance of ADS-TEC Energy’s systems are the result of extensive investment in in-house development and high levels of vertical integration. With its advanced technology platforms, ADS-TEC Energy is a trusted partner for automotive manufacturers, energy providers, and charging infrastructure operators worldwide.

For more information, visit: www.ads-tec-energy.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420342686/en/

Media Contact:

For ADS-TEC Energy:

Katharina Decken

Marketing & Communications

[email protected]

KEYWORDS: Germany Europe United States North America

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Technology EV/Electric Vehicles Automotive Other Energy Utilities Software Alternative Energy Energy Batteries

MEDIA:

Photo

ADS-TEC Energy is exhibiting at the Baden-Württemberg pavilion in Hall 12, Booth E63.

April 20, 2026 9:06 am

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Transaction will add pro-forma profitable revenue, enhance predictability of financial performance, expand market share, and accelerate the Company’s path to sustainable cash-based EBITDA profitability. Management encourages Shareholders to vote in favor of the proposal.

SANTA MONICA, Calif., April 20, 2026 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, issued a letter to shareholders from the Company’s Chairman and Chief Executive Officer, Matt Edelman.

Dear Fellow Shareholders,

We recently announced our agreement to acquire the Misfits Ads Division. Already generating profitable revenue, integrating the division is fully expected to improve the predictability of our performance, expand our market share, and accelerate our path to cash-based EBITDA profitability. We believe it is an important step and ideal opportunity for Super League to build sustainable operating momentum and shareholder value following the work we completed in 2025 to create a stable corporate foundation for growth.

This strategic acquisition will make us a stronger company with a clearer and faster path to EBITDA profitability and a more defensible moat around our business.

Super League became a new and revitalized company over the past year as a result of the restructuring work we undertook with both new and existing financial supporters excited about our strategic plan. We have sufficient capital resources to fund operations for the foreseeable future, a capital structure enabling organic and inorganic growth, and a more efficient operation supporting year-over-year revenue expansion.

The Misfits Ads Division is set to accelerate that progression. It is a profitable business unit today and is expected to have an immediate accretive impact on our cash-based EBITDA. We expect that impact to begin to be visible soon after the acquisition closes, and for this transaction to be a key driver supporting our path to cash-based EBITDA profitability by year end.

The acquisition also improves the diversification and quality of our revenue. Today, a meaningful portion of our business is driven by custom campaign work. While Super League is highly regarded in this area, Misfits adds programmatic advertising capabilities, which are transaction-based and generally more recurring in nature. This will result in a more dependable and predictable revenue foundation over time.

In addition, the transaction brings proprietary technology that supports revenue generation in channels where we have historically relied on third-party solutions. By owning more of the underlying technology and capabilities, we expect to improve margins and strengthen our competitive position.

Upon the closing of the transaction, Super League will also have a preferred commercial partnership with Misfits Gaming Group, enabling the Company to secure revenue-generating brand deals across a portfolio of Roblox games that reach more than 100 million monthly active users.

The Misfits Ads Division has executed more than 150 brand partnership programs in the past three years. Integrating the Misfits Ads Division team will expand our scale in the gaming media sector, increasing our relationships with brands and agencies, adding to our sales capacity, and broadening our pipeline of opportunities. Super League will be larger, more diverse and an even more relevant participant in a growing market.

This transaction is happening at exactly the right time—the market opportunity is significant. Consumers spend nearly as much time playing video games as they do on social media and watching television and streaming. Yet while advertising spend across those channels exceeds $150 billion annually in the U.S., total spend in gaming remains near just $10 billion.

This gap between consumer time spent and brand dollars invested is Super League’s core opportunity. We believe this transaction strengthens our ability to capture a greater share of ad spend from the ever-increasing number of brands shifting attention to this vastly under-monetized consumer segment.

Taken together, these factors—profitable revenue, improved predictability, expanded scale, and greater ownership of technology—represent a significant step forward for Super League and reinforce the progress we have made over the past year.

We strongly encourage you to vote in favor of the transaction to help unlock the next phase of growth and opportunity for our Company. Thank you for your continued support.

Sincerely,
Matt Edelman
Chief Executive Officer
Super League Enterprise, Inc.

About Super League Enterprise:

Super League (Nasdaq: SLE) connects brands with the 3.5 billion-person global gaming population through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this highly engaged yet under-monetized audience, Super League is positioned to capture an increasing share of brand advertising spend as the market evolves.

Forward-Looking Statements

Forward Looking Statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements include all statements other than statements of historical fact, including, without limitation, all statements regarding the private placement, including expected proceeds, Super League’s ability to maintain compliance with the Listing Rules of the Nasdaq Capital Market, statements regarding expected operating results and financial performance (including the Company’s commitment to and ability to achieve Adjusted EBITDA-positive results in Q4), strategic transactions and partnerships, and capital structure, liquidity, and financing activities. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which the Company operates, management’s current beliefs, and certain assumptions made by the Company, all of which are subject to change.

Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that are difficult to predict, and that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Important factors include, but are not limited to: the Company’s ability to adequately utilize the funds received recent financings; the Company’s ability to execute on cost reduction initiatives and strategic transactions; customer demand and adoption trends; the timing, outcome, and enforceability of any patent applications; the ability to successfully integrate new technologies and partnerships; platform, regulatory, macroeconomic and market conditions; the Company’s ability to maintain compliance with Nasdaq Capital Market continued listing standards; access to, and the cost of, capital; and the other risks and uncertainties described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, and other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Kirsten Beduya
Quantum Media Group
[email protected]

April 20, 2026 9:05 am

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness. GH Research continues to advance GH001, its proprietary inhaled mebufotenin product candidate, toward initiation of a global pivotal Phase 3 program in treatment-resistant depression (TRD) in 2026.

“We commend the Administration for recognizing the magnitude of the mental health crisis and the urgent need for innovative, evidence-based therapies for patients with serious mental illness. The Executive Order’s emphasis on scientific rigor and cross-agency coordination is well aligned with the approach required to deliver practice-changing treatments, and we remain focused on advancing GH001 toward a global pivotal Phase 3 program,” said Dr. Velichka Valcheva, Chief Executive Officer of GH Research.

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.

About GH001

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), we believe that GH001 has the potential to change the way TRD is treated today.

Forward-Looking Statements

This press release contains statements that are, or may be deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding the potential impact of the Executive Order on the regulatory environment and on the development of psychedelic medical treatments, including our mebufotenin product candidates, and our plans and expectations with respect to the initiation, timing, progress and design of our global Phase 3 pivotal program for GH001, are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, the risk that the Executive Order may not be implemented as anticipated, may be modified, delayed, challenged, rescinded or superseded, and may not, in practice, accelerate the development or approval of psychedelic medical treatments, including our mebufotenin product candidates; the risk that we may not be able to initiate or complete our global Phase 3 pivotal program for GH001 on the timelines we are targeting or at all; the risk that we may not obtain FDA alignment on the pivotal program design on favorable terms or at all; and those other risks described in our filings with the U.S. Securities and Exchange Commission from time to time. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Relations

Julie Ryan
GH Research PLC
[email protected]

April 20, 2026 9:05 am

KUSTOM ENTERTAINMENT, INC. ANNOUNCES PLANNED ADDITION OF FOURTH CONCERT DAY IN THE SECOND QUARTER OF 2026

New event initiative expected to build on seasonal demand and audience momentum surrounding global sports enthusiasm and Country Stampede

OVERLAND PARK, KS, April 20, 2026 (GLOBE NEWSWIRE) — Kustom Entertainment, Inc. (Nasdaq: KUST) (“Kustom” or the “Company”), a premier creator of live music experiences and ticketing solutions, today announced plans to add a fourth concert day during the second quarter of 2026. Further information will be announced at a later date.

Expansion of Q-2 2026 Event Calendar

Building on the momentum of its flagship festival, Country Stampede, Kustom plans to add a fourth major concert day in the second quarter of 2026. This initiative is designed to capitalize on the heightened tourism and regional activity surrounding global sports events scheduled in the Kansas City area during the summer of 2026. Details regarding the additional event date, official name, music genre, and artist lineup will be announced at a later date.

“This pivot marks a defining moment for Kustom,” said Stan Ross, CEO of Kustom Entertainment, Inc. “By divesting our unrelated legacy businesses, we are now a pure-play entertainment company. Adding a fourth concert day in Q-2 is the first step in our aggressive growth strategy to capture the surge in regional foot traffic and ‘global sports fever’ hitting our backyard this year.”

Ross added “The planned addition reflects Kustom’s strategy to identify timely market opportunities, broaden fan engagement, and enhance the value of its event platform through targeted programming aligned with current consumer interest. Management believes the additional second-quarter event will complement the company’s existing concert offerings while supporting broader brand visibility and audience growth.”

For more information and future updates, visit www.Kustom440.com.

30th Anniversary Country Stampede Lineup

The Company is also proud to finalize the lineup for the 30th Anniversary of Country Stampede, held June 25–27, 2026, at the Azura Amphitheater in Bonner Springs, KS.

Feature	Details
Headliners	Rascal Flatts, Zach Top (2025 CMA New Artist of the Year), Treaty Oak Revival
Main Stage Support	Scotty McCreery, Wyatt Flores, Tracy Lawrence, Diamond Rio, Jerrod Niemann
Emerging Talent	Lanie Gardner, Presley & Taylor, The Wilder Blue
Opening Act	Isaac Cole (2026 Battle of the Bands Winner)
Events	Kickoff Party (June 24 at Hollywood Casino), Downtown Pre-party, and Nightly After-parties

“The 2026 lineup represents our commitment to blending legendary headliners with the industry’s fastest-rising stars,” said Matt Tholen, Vice President of Operations. “We aren’t just selling tickets; we are building a three-decade legacy of community-focused entertainment.”

Tickets, camping and VIP experiences are available now at www.CountryStampede.com.

About Kustom Entertainment, Inc.

Kustom Entertainment, Inc. is a leader in live event production and ticketing technology, specializing in large-scale music festivals and end-to-end event management. Its flagship event, Country Stampede, is held annually during June at the Azura Amphitheater in Bonner Springs, Kansas.

The Company also maintains a legacy segment engaged in video solution technology (in-car and body-worn cameras) for law enforcement and security, currently integrating artificial intelligence to enhance its specialized product lines.

For additional information, please visit www.kustoment.com and www.digitalally.com.

Forward-Looking Statements

Statements made in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. You should not place undue reliance on such forward-looking statements, which are based on the information currently available to us and speak only as of today’s date. All statements other than statements of historical fact are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made, and the Company assumes no duty to update forward-looking statements, except as required by law. Actual future results, performance or achievements may differ materially from historical results or those anticipated depending on a variety of factors, some of which are beyond the control of the Company, including, but not limited to, the risks described from time to time in the Company’s periodic filings with the U.S. Securities and Exchange Commission, including, without limitation, the risks described in the Company’s 2025 Annual Report on Form 10-K under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (as applicable). These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and the Company undertakes no duty to update this information.

For Additional Information, Please Contact:

Stanton E. Ross, CEO at (913) 456-5878

April 20, 2026 9:05 am

Leverage Shares by Themes Announces ETF Share Splits

GREENWICH, Conn., April 20, 2026 (GLOBE NEWSWIRE) — Leverage Shares by Themes, a trusted provider of single stock leveraged ETFs, announce a 1:20 reverse stock split on two of their ETFs. All reverse splits will be effective prior to market open on April 24, 2026, when the funds will begin trading at their post-split prices.

The reverse splits will increase the price per share of each fund, with a proportionate decrease in the number of shares outstanding. The splits will not change the total value of a shareholder’s investment.

Leverage Shares by Themes will implement a 1:20 reverse split on the following ETFs:

Ticker	Leverage Shares ETF	Split Ratio	Original CUSIP	New CUSIP
BULG	Leverage Shares 2x Long BULL Daily ETF	1:20	88340C701	88340C347
GEMG	Leverage Shares 2x Long GEMI Daily ETF	1:20	88340C735	88340C354

The tickers for the funds will not change. All funds undergoing a reverse split will be issued new CUSIP numbers.

Illustration of a Reverse Split

Consider a hypothetical example. In a one-for-five reverse split, every five pre-split shares result in the receipt of one post-split share and will be priced five times higher than the net asset value (“NAV”) of a pre-split share. The following table shows the effect of the hypothetical one-for-five reverse split:

Period	# of Shares Owned	Hypothetical NAV	Value of Shares
Pre-Split	100	$10.00	$1,000.00
Post-Split	20	$50.00	$1,000.00

Fractional Shares from Reverse Splits

For shareholders who hold quantities of shares that are not an exact multiple of the reverse split ratios (for example, not a multiple of five for a one-for-five reverse split), the reverse splits will result in the creation of fractional shares. Post-reverse split fractional shares will be redeemed for cash and sent to your broker of record. This redemption may cause some shareholders to realize gains or losses, which could be a taxable event for those shareholders.

For more information about these ETFs and other products offered by Leverage Shares by Themes, please visit www.leverageshares.com/us

For media inquiries, please contact:

Arielle Shternfeld, Director, Communications and Advisor Relations
[email protected]
+1 (860) 716-3686

About Themes ETFs:

Themes ETFs was established by the Co-Founders of Leverage Shares in 2023 to offer thematic and sector-based products in the US. Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. Themes ETFs seeks to provide investors with targeted exposure to specific segments of the market via its low-cost ETFs. For more information, visit www.themesetfs.com.

About Leverage Shares:

The company was launched in 2017 by CEO Jose Gonzalez-Navarro, COO Dobromir Kamburov and General Counsel Tracy Grant (the “Co-Founders”) and has 160+ ETPs offering both leveraged and unleveraged exposure to single stocks, ETFs and commodities across various exchanges in Europe. For more information, please visit www.leverageshares.com

INVESTMENT INVOLVES SIGNIFICANT RISK. Fund does not invest directly in the underlying stock. As with any investment, there is a risk that you could lose all or a portion of your investment in the Fund.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about Themes ETFs. To obtain a Fund’s prospectus and summary prospectus call 886-584-3637. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Newly launched Funds have risks associated with a limited operating history.

Because of daily rebalancing and the compounding of each day’s return over time, the return of the Fund for periods longer than a single day will be the result of each day’s returns compounded over the period, which will very likely differ from 200% of the return of the underlying stock over the same period. The Fund will lose money if the underlying stock performance is flat over time, and because of daily rebalancing, the underlying stock’s volatility, and the effects of compounding, it is even possible that the Fund will lose money over time while the underlying stock’s performance increases over a period longer than a single day. The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Fund will lose money if the underlying stock’s performance is flat, and it is possible that the Fund will lose money even if the underlying stock’s performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day if the price of the underlying stock falls by more than 50% in one trading day.

Under the Investment Advisory Agreement between the Adviser and the Trust, on behalf of the Fund (the “Investment Advisory Agreement”), the Adviser has agreed to pay all expenses of the Fund, except for the fee paid to the Adviser pursuant to the Investment Advisory Agreement, interest charges on any borrowings, taxes, brokerage commissions and other expenses incurred in placing orders for the purchase and sale of securities and other investment instruments, acquired fund fees and expenses, accrued deferred tax liability, extraordinary expenses, and distribution (12b-1) fees and expenses.

Past performance does not guarantee future results.

INVESTMENT RISKS: Investing in the Funds involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

Investment in leveraged products may be subject to higher volatility. Fund does not directly invest in the underlying stock. An investment in the Fund involves risk, including the possible loss of principal. The Fund is non-diversified and includes risks associated with the Fund concentrating its investments in a particular industry, sector, or geographic region which can result in increased volatility. The use of derivatives such as futures contracts and swaps is subject to market risks that may cause their price to fluctuate over time. Risks of the Fund include effects of Compounding and Market Volatility Risk, Inverse Risk, Market Risk, Counterparty Risk, Rebalancing Risk, IntraDay Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, and risks specific to the securities of the Underlying Stock and the sector in which it operates. These and other risks can be found in the prospectus.

For periods longer than a single day, the Funds will lose money if BULL or GEMI, respectively, has flat performance, and it is possible that the Funds will lose money even if BULL or GEMI performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day if the price of BULL or GEMI falls by more than 50% in one trading day.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (NBBO) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses, or sales charges. One cannot invest directly in an index.

This information is not an offer to sell or a solicitation of an offer to buy shares of any Funds to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction.

Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. The funds are distributed by ALPS Distributors, Inc (1290 Broadway, Suite 1000, Denver, Colorado 80203). ALPS is not affiliated with any mentioned entity. Client brokerage services not offered by ALPS. Please see third party site for more information about any mentioned services. Themes ETFs are not sponsored, endorsed, issued, sold, or promoted by these entities, nor do these entities make any representations regarding the advisability of investing in the Themes ETFs. Neither ALPS Distributors, Inc, Themes Management Company LLC nor Themes ETFs are affiliated with these entities. Themes Management Company LLC and Leverage Shares are affiliates that are under common control. Themes Management Company and Leverage Shares have entered into a licensing agreement in which Leverage Shares licenses the trademark LEVERAGE SHARES to Themes Management Company LLC for use in financial services in the United States.

April 20, 2026 9:05 am

Wearable Devices Announces Collaboration with Meta-Bounds to Enable Intuitive Neural Control for AR Glasses

Partnership outlines short-term integration for intuitive “spatial interaction” and long-term commercial models for enterprise AR solutions, with demos planned for the AWE 2026.

Yokneam Illit, Israel, April 20, 2026 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a future cooperation and partnership with Meta-Bounds Inc. The collaboration aims to integrate Mudra’s neural wristband technology with Meta-Bounds’ augmented reality (“AR”) hardware to deliver a seamless user experience.

Wearable Devices and Meta-Bounds (together, the “Companies”) are planning to collaborate and officially showcase the results of this partnership during the upcoming Augmented World Expo 2026 convention in Long Beach, California, United States.

Roadmap: Short-Term and Long-Term Cooperation

The Companies have outlined a comprehensive future cooperation planning framework to bring this technology to market.

The short-term focus includes:

● Developing preliminary wristband control for AR glasses, creating a basic technology chain to achieve intuitive “spatial interaction”.

To support long-term global scaling and address diverse B2B market needs, a primary commercial model has been established:

● Enterprise Partnership Phase: The second phase of collaboration will integrate Mudra as a premium accessory for Meta-Bounds’ B2B clients.

The Companies may also explore a possible continuation of the collaboration based on providing customized, value-added resale solutions integrated directly into Meta-Bounds’ full-stack augmented reality products.

About Meta-Bounds

Meta-Bounds stands as a global trailblazer in consumer-level AR technologies, including near-eye display, perceptual interaction and mass production. Based on world-leading AR technologies, Meta-Bounds stands out on the world stage, paving a new direction of ultra lightweight AR glasses for the industry. Since 2022, Meta-Bounds has collaborated with global technology conglomerates such as SoftBank Group Corp., Guangdong OPPO Mobile Telecommunications Corp., Ltd., ZTE Corporation, Lenovo Group Limited, Baidu, Inc., Shenzhen Transsion Holdings Co., Ltd., Otsuka Corporation, and Hubei DreamSmart Group Co., Ltd., launching multiple new-generation consumer level AR glasses, maintaining and repeatedly breaking the world record for the most lightweight AR glasses.

About Wearable Devices

Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) is a growth company pioneering human-computer interaction through its AI-powered neural input touchless technology. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company’s consumer products – the Mudra Band and Mudra Link – are defining the neural input category both for wrist-worn devices and for brain-computer interfaces. These products enable touch-free, intuitive control of digital devices using gestures across multiple operating systems. Operating through a dual-channel model of direct-to-consumer sales and enterprise licensing and collaborations, Wearable Devices empowers consumers with stylish, functional wearables for enhanced experiences in gaming, productivity, and XR. In the business sector, the Company provides enterprise partners with advanced input solutions for immersive and interactive environments, from augmented reality/virtual reality/XR to smart environments. By setting the standard for neural input in the XR ecosystem, Wearable Devices is shaping the future of seamless, natural user experiences across some of the world’s fastest-growing tech markets. Wearable Devices’ ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols “WLDS” and “WLDSW,” respectively.

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, we are using forward-looking statements when we discuss the benefits and advantages of our technology and products, our future cooperation and partnership with Meta-Bounds, and the Companies’ possible continuation of the collaboration based on providing customized, value-added resale solutions integrated directly into Meta-Bounds’ full-stack augmented reality products . All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2025, filed on March 12, 2026 and our other filings with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty

[email protected]

April 20, 2026 9:05 am

GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm

PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) — Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) (“Gyre”) on behalf of the company’s investors.  

The investigation seeks to determine whether Gyre and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.  

Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 – 0750, by email at

[email protected]

, or by filling out our online form at:

https://kaskelalaw.com/case/gyre-therapeutics/

ABOUT KASKELA LAW:

Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about the firm, including our recent monetary recoveries for investors, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 – 1740.

KASKELA LAW LLC
D. Seamus Kaskela, Esquire
Adrienne Bell, Esquire
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com

This communication may constitute attorney advertising in certain jurisdictions.

April 20, 2026 9:05 am

Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026

PALO ALTO, Calif., April 20, 2026 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the “Scilex Board”) approved a dividend of Dream Bowl I Meme Coin Tokens held by the Company (the “Dream Bowl Tokens”) to its stockholders and certain other eligible equityholders of Scilex (collectively, the “Participating Holders”). The record date for the Dividend is April 30, 2026 (the “Record Date”).

The Participating Holders as of the Record Date will be entitled to receive five (5) Dream Bowl Tokens for each share of Scilex common stock held (or for each share of common stock issuable or deemed issuable upon exercise or conversion of such other eligible securities). Scilex currently holds approximately 268 million Dream Bowl Tokens and plans to distribute approximately 81.4 million of such Dream Bowl Tokens to the Participating Holders.

The Record Date for the dividend may be changed by the Scilex Board for any reason at any time prior to the actual payment date, and payment of the dividend is conditioned upon the Scilex Board having not revoked the dividend prior to the payment date, including for a material change to the solvency or surplus analysis presented to the Scilex Board. Subject to the right of the Scilex Board to change the Record Date, the payment date for the dividend will be determined by subsequent resolutions of the Scilex Board, which payment date will be within 60 days following the Record Date (the “Payment Date”).

It is anticipated that in order to receive the Dream Bowl Tokens, the Participating Holders will be required to open a digital wallet with Datavault AI Inc. (“Datavault”) and execute an Opt-In Agreement, pursuant to which such holders will agree, among other things, to the payment conditions set forth therein, and acknowledge that such holders understand the process for receiving the Dream Bowl Tokens, that the Scilex Board can change the Record Date or Payment Date or revoke the distribution prior to the Payment Date, and that the Dream Bowl Tokens may not have or maintain any value.

The Company will provide further instructions regarding wallet setup, token access, and distribution process in a subsequent communication prior to the Payment Date to ensure that all eligible Participating Holders can properly claim and view their tokens.

Scilex intends to list the Dream Bowl Tokens on the Biconomy exchange (“Biconomy” – biconomy.com), a global centralized cryptocurrency exchange at a later date. Scilex believes that such listing may deliver liquidity and allow for broad distribution of such tokens for the Participating Holders.

The Dream Bowl Token is a digital collectible intended solely for personal, non-commercial use. The Dream Bowl Token does not in and of itself: (i) represent or confer any equity, voting, dividend, profit-sharing, or ownership rights in Scilex or any other entity (including Datavault); (ii) provide any right to receive monetary payments, distributions, or appreciation; or (iii) create any expectation of profit or reliance on the managerial or entrepreneurial efforts of Scilex or others. The Dream Bowl Token is not designed or intended to function as an investment, currency, or financial product, and it is not being offered, sold, or distributed for fundraising or capital-raising purposes. Use of the Dream Bowl Token is limited to entertainment, event-access, and digital-collectible functions. Any transferability features are provided solely to support personal digital item portability and not to facilitate or imply investment or speculative use.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

[email protected]

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, including Scilex’s potential distribution of the Dream Bowl Tokens and the timing thereof (including that the Payment Date will be determined by subsequent resolutions of the Scilex Board, and that the Scilex Board may change the Record Date and, as a result, the Payment Date, once determined) and the Company’s intention to deliver liquidity and broad distribution of the Dream Bowl Tokens. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risks and uncertainties include, but are not limited to, risks related to legal proceedings that may be instituted against Scilex regarding the Dream Bowl Tokens and the distribution thereof to the Company’s eligible equityholders; risks associated with the right of the Scilex Board to change the Record Date and the Payment Date of the distribution of, and/or to revoke, the dividend of the Dream Bowl Tokens; general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

April 20, 2026 9:05 am

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity

Atebimetinib-treated tumors rarely acquire the genetic alterations most commonly associated with resistance to RAS inhibitors, providing molecular rationale to treat with atebimetinib early

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the presentation of new genetic data at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA.

“Atebimetinib is designed to promote survival by three mechanisms: shrinking tumors durably, preserving body mass by counteracting muscle wasting, and maintaining performance status by maximizing tolerability,” said Ben Zeskind, Ph.D., Chief Executive Officer of Immuneering. “We believe these characteristics have the potential to both yield the best survival in the first-line, and to give patients the best chance of reaching and benefitting from second-line treatment. Today’s data at AACR add genetic rationale to support atebimetinib’s observed durable tumor shrinkage and its optimal use in the first-line setting by showing that the most common RAS-inhibitor resistance mechanisms are rarely seen in atebimetinib-treated patients.”

Inhibitors of RAS, RAF, or MEK often provide only temporary benefit due to pervasive resistance, as tumors acquire new mutations or mechanisms of escape within the MAPK pathway. Atebimetinib, a novel Deep Cyclic Inhibitor of MEK, is engineered to mitigate the selective pressure that typically drives these resistance mechanisms, with the goal of more durable anti-tumor activity. Immuneering presented circulating tumor DNA (ctDNA) data from 123 patients treated with atebimetinib, showing that acquired MAPK pathway alterations are rarely seen. These findings suggest that Deep Cyclic Inhibitors have the potential to overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients, while potentially preserving sensitivity to subsequent treatments.

Key Findings from the AACR Presentation:

Rare MAPK pathway reactivation: Across 86 patients treated with atebimetinib monotherapy and 37 patients treated in combination with chemotherapy, emergent and acquired mutations rarely converged on the RAS/MAPK pathway, in contrast to what is commonly observed with chronic RAS-targeted therapies.
Diffuse, non-convergent resistance patterns: Emergent resistance following atebimetinib treatment utilized a variety of non-MAPK pathways, rather than converging on a single escape mechanism.
Limited early adaptive resistance: ctDNA analysis showed minimal early molecular evolution during treatment, indicating that atebimetinib is not driving adaptive resistance and may impose less selective pressure than continuous pathway inhibition.
Taken together, the data position atebimetinib as a differentiated MEK inhibitor with potential to drive deep and durable antitumor activity.

“Our AACR data further validate the scientific foundation of our platform, demonstrating that Deep Cyclic Inhibition can fundamentally alter how tumors evolve under therapy, unlocking opportunities to improve treatment durability,” said Brett Hall, Ph.D., Chief Scientific Officer of Immuneering. “Deep Cyclic Inhibition of MEK avoids the continuous selective pressure that typically drives tumors to become resistant to treatment via reactivation of the MAPK pathway. This, combined with atebimetinib’s tolerability profile, has the potential to improve depth and durability of response in a broad range of cancers, starting with first-line pancreatic cancer.”

Poster Presentation Details:

Title: Atebimetinib’s Deep Cyclic Inhibition of MEK Constrains MAPK-Axis Adaptive and Acquired Alterations in Patients with RAS-Mutant Tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Drug Resistance 2: RAS Signaling
Poster Number: 1873
Poster Board Number: 6
Session Date: April 20, 2026
Session Time: 9:00 AM – 12:00 PM ET
Location: Poster Section 19

The poster is available on the publications section of Immuneering’s website at https://immuneering.com/publications.

Immuneering has guided to dosing the first patient in its pivotal Phase 3 MAPKeeper 301 trial of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in patients with first-line metastatic pancreatic cancer in mid-2026. In the second half of the year, the company expects to dose the first patient in a Phase 2 trial of atebimetinib plus Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer.

About Immuneering

Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and its potential to deliver overall survival with both durability and tolerability; the timing of dosing of additional studies, the ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition, including to impose less selective pressure, and provide a more sustained clinical benefit for patients.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact:

Courtney Dugan
[email protected]

Media Contact:

Peg Rusconi
[email protected]